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1 
GENERAL INTRODUCTION 
INTRODUCTION 
Antiresorptive drugs 
Antiresorptive drugs (ARDs) are used to decrease the rate of bone turnover by 
suppression of osteoclast-mediated bone resorption and thereby improving bone 
mineral density (BMD) and minimizing the loss of bone mass.  Several well-
controlled clinical trials have reported that ARDs are effective in the management of 
osteoporosis, multiple myeloma and metastatic bone disease [1]. These medications 
include bisphosphonates (BPs) and, more recently, receptor activator of nuclear factor 
kappa-B ligand (RANKL) inhibitor (denosumab).  
Indications 
Skeletal-related effects (SREs), namely pathological fracture, spinal cord 
compression, radiation or operative intervention and bone pain, are common among 
oncology patients. SREs can negatively affect functionality and health-related quality 
of life [2]. ARDs were shown to decrease SREs and subsequently can improve quality 
of life and minimize morbidity [3, 4]. Furthermore, recent studies have suggested that 
ARDs can be useful in suppressing bone involvement with solid tumors [5, 6].  
ARDs are considered revolutionary treatment for not only metastatic bone disease and 
multiple myeloma but also for osteoporosis. It has been shown that ARDs can 
decrease fracture rates and improve BMD in osteoporosis patients [7]. In 1995, the 
Food and Drug Administration (FDA) granted approval to alendronate for 
postmenopausal osteoporosis [8]. Alendronate was reported to minimize the rate of 
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vertebral fracture by 70% and hip fracture by 50% [9]. In June 2010, the FDA 
approved denosumab for osteoporosis and it became, therefore, the first biological 
therapy for this indication [10]. FREEDOM (Fracture Reduction Evaluation of 
Denosumab in Osteoporosis every 6 Months) Extension is a Phase III trial conducted 
to detect the long-term effect of denosumab in the treatment of postmenopausal 
osteoporosis over 10 years [11, 12]. This study found a persistent increase in BMD, 
with a 10 year-cumulative gain of 21.7% at lumbar spine and 9.2% at total hip [11]. In 
addition, a continued decline in vertebral and non-vertebral fracture rates was 
observed, 0.9 to 1.86% and 0.84 to 2.55% after 10 years of denosumab treatment, 
respectively. The occurrence of side effects did not increase over the 8 years and a 
favorable benefit/risk profile was evident. The persistent increase in BMD observed 
with denosumab is crucial as BMD tend to plateau after 3 years of BPs administration 
[13]. In Japan, Denosumab Fracture Intervention Randomized Placebo-Controlled 
Trial (DIRECT), a double-blind placebo-controlled trial, investigated denosumab in 
osteoporotic patients [14]. In this trial, a consistent increase of BMD and significant 
reduction of fractures and bone remodeling markers were observed. Furthermore, 
several clinical trials have shown that denosumab has a greater impact than BPs in 
increasing BMD, lowering bone turnover markers and minimizing fracture rate [15, 
16]. Besides the above-mentioned clinical applications, ARDs are indicated for the 
treatment of some other rare bone conditions such as giant cell tumor, Paget’s disease 
of bone and osteogenesis imperfecta [17-19].  
Mechanism of action 
Although both denosumab and BPs are ARDs and result in inhibition of osteoclasts, 
their mechanisms of action are totally different. BPs are chemically stable derivatives 
of inorganic pyrophosphates which adsorb onto bone hydroxyapatite crystals and 
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induce osteoclast apoptosis [20]. In contrast, denosumab is a human monoclonal 
antibody of RANKL [21]. RANKL is a cytokine synthesized by osteoblasts and binds 
to the receptor activator of nuclear factor kappa-B (RANK) receptor of preosteoclasts 
and induces thereby the differentiation of preosteoclasts to osteoclasts [22]. 
Denosumab binding to RANKL can suppress the development and maturation of 
these cells and lead to prevention of bone resorption [23]. BPs incorporate into 
osteoclasts and promote their apoptosis. In contrast, denosumab acts extracellularly 
and prevents osteoclasts maturation and formation. Moreover, denosumab does not 
persist in bone tissue and has a short half-life of only 26 days [23]. Denosumab is 
eliminated via the reticuloendothelial system and not via kidneys [20]. Therefore, 
unlike BPs, the renal function does not significantly influence denosumab use [24, 
25]. 
Side effects 
Despite their wide benefits, BPs can result in potentially serious side effects. Short-
term side effects can occur after initiation of therapy and include gastrointestinal 
complications, fever, myalgias, arthralgias, musculoskeletal pain and hypocalcemia 
[8]. The long-term complications of BPs include osteonecrosis of the jaw, 
subtrochanteric femoral fracture and atrial fibrillation [8, 26].  
Dyspnea, fatigue and hypophosphatemia are among the most common complications 
of denosumab [10]. Osteonecrosis of the jaw was also observed during denosumab 
treatment and is one of the most common causes of treatment discontinuation [27]. 
Another serious complication that can also lead to denosumab cessation is 
hypocalcemia [12]. RANKL and RANK are expressed also in activated B 
lymphocytes. Therefore, long-term administration of denosumab might suppress 
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immunity and raise the risk of infection. However, this risk has not been proven in 
humans, although it was observed in preclinical animal studies [10, 12].  
 Medication-related osteonecrosis of the jaws (MRONJ) 
ARDs are effective medications in inhibition of bone turnover and can lessen 
morbidity and enhance the quality of life of osteoporosis and cancer patients. 
However, it has been well established that MRONJ is a rare complication of these 
medications, which can also influence the quality of life and require complex 
treatments and long follow-ups [28].  
Definition  
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) was initially described by 
Marx in 2003 [29]. After that, thousands of cases have been reported. In 2007, the 
American Association of Oral and Maxillofacial Surgeons (AAOMS) held a special 
committee to set a definition for this new potentially debilitating complication [30]. A 
definition of BRONJ was proposed as bone exposure in the maxillofacial region in 
patients underwent BP treatment, which didn’t heal for 8 weeks and with no 
associated history of radiation to the jaws. In 2009, AAOMS updated her position 
paper to include the unexposed variant of BRONJ [31]. Several years after the first 
report of BRONJ, denosumab-related osteonecrosis of the jaw (DRONJ) was also 
identified in denosumab clinical studies in oncology and osteoporotic patients [14, 25, 
32-41]. More cases were reported following denosumab’s approval for clinical use in 
2010 [42-48]. Aiming to include osteonecrosis lesions diagnosed after denosumab and 
antiangiogenic agents administration, the AAOMS has changed the nomenclature 
from BRONJ to MRONJ in its 2014 position paper [49]. In this paper, MRONJ has 
been defined as exposed bone or bone that can be detected via a fistula in the 
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maxillofacial region that persisted for 8 weeks in patients with current or previous 
treatment with ARDs or antiangiogenic medications and who did not have 
radiotherapy or obvious metastasis to this anatomic site [49]. 
Incidence 
MRONJ is a relatively rare complication of ARDs. Several studies aimed to find the 
incidence and prevalence of MRONJ. However, most of these studies are based on 
medical record reviews, mailed surveys or insurance data. Moreover, the incidence of 
MRONJ is likely to be underestimated as some lesions can be mild and remain 
undiagnosed. In general, the prevalence of MRONJ in oncology patients treated with 
intravenous BPs was estimated to be from 1.2% to 9.9% [50]. This incidence in 
patients with multiple myeloma is 4.5 folds more than that among patients with breast 
cancer [51]. An Australian national survey estimated MRONJ risk of 0.01% to 0.04% 
in patients receiving oral BPs for osteoporosis [52]. The risk increased to 0.34% in 
patients with a history of dental extraction. A large postal survey included 8,572 
osteoporotic patients on oral BPs and found a prevalence of  0.10% [53]. 
 Likewise, DRONJ was reported to develop in cancer and osteoporosis patients [43, 
49]. As estimated by combined 3 blinded phase 3 trials of 5,723 oncology patients 
under zoledronate or denosumab, the incidence of MRONJ was 0.5% or 0.8% at 12 
months, 1.0% or 1.8% at 24 months, and 1.3% or 1.8% at 36 months of ARD intake, 
respectively [32]. A plateau was observed after 24 months of denosumab 
administration. The reported incidence of MRONJ was higher in patients receiving 
denosumab (1.8%) in comparison to those receiving zoledronate (1.3%). However, 
the cumulative incidence of MRONJ was almost similar for the two medications [32]. 
The median duration of ARDs before diagnosis was 14 months. According to the 
results of FREEDOM trial, only seven DRONJ cases were detected in the long-term 
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group (1343 patients) who received denosumab for 10 years and six cases in the 
crossover group (1283 patients) who received denosumab for 7 years [12].  
Pathogenesis 
Despite the enormous amount of literature generated over more than a decade, the 
pathogenesis of MRONJ is still not completely elucidated. Many theories have been 
proposed for the pathogenesis of MRONJ. However, none of them is supported by 
robust scientific evidence. It is likely that many factors are contributing to MRONJ 
onset and responsible for its unique localization in the jaws. ARDs act by suppressing 
bone remodeling, which is indeed essential to neutralize bone microdamage. This 
process is particularly important in the jawbones, which are more vulnerable to 
microtraumas caused by masticatory forces and bacterial infection due to the presence 
of the teeth and the oral flora. Otto et al. suggested that local infection, mainly 
periodontitis, can increase local acidity and subsequently can induce the release of 
BPs and maximize their toxic effects [54, 55]. This can explain the high incidence of 
MRONJ at sites of dental extractions, as most of them are indicated due to local 
infection, and at sites of periodontitis [56]. 
Risk factors 
The determination of the risk factors related to MRONJ is nearly impossible due to 
the lack of well-controlled prospective studies. In fact, the conduction of such studies 
in relation to MRONJ would be unethical. In addition, it is very difficult to investigate 
risk factors in cancer and osteoporosis patients who have multiple comorbidities and 
high-risk medications. However, many potential risk factors seem to contribute 
significantly to MRONJ development. One of the established risk factors is the drug 
itself, including its duration of intake, dose and potency [57]. Moreover, concomitant 
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chemotherapy and antiangiogenic agents were shown to aid in MRONJ development 
[58, 59]. Several studies reported diabetes mellitus and corticosteroids as risk factors 
[60, 61]. On the other hand, some studies found almost the same number of patients 
with a history of corticosteroids in the control group [62, 63]. Local factors such as 
tooth extraction, local surgery, periodontitis and chronic local trauma caused by ill-
fitting prosthesis can obviously trigger MRONJ onset and were reported almost in 
every case series [59, 64]. Therefore, optimizing oral health before and after ARDs 
administration can minimize these local factors and thus can diminish the risk of 
MRONJ.  
Clinical staging 
The AAOMS proposed a staging system for MRONJ (stage 0 to 3) [49]. Stage-
specific therapeutic strategies, although are not supported by strong evidence, were 
also suggested. These stages can be summarized as the following: 
Stage 0: nonspecific signs and symptoms, radiographic alterations in absence of 
exposed bone. 
Stage 1: exposed bone or fistula to the underlying hard tissue in absence of pain and 
infection. 
Stage 2: exposed bone or fistula to the underlying hard tissue with infection and/or 
pain. 
Stage 3: exposed bone or fistula to the underlying hard tissue with pain and/or 
infection, in combination with one of these conditions: involvement of structures 
other than the alveolar bone leading to pathologic fracture, fistula or maxillary sinus 
involvement. 
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This system has several pitfalls, which have been discussed by several authors [65, 
66]. Nevertheless, it is the most widely used and accepted staging system of MRONJ 
so far. 
Differential diagnosis 
The clinician should be aware of the lesions, which could have a similar clinical 
presentation to MRONJ in order to avoid errors in diagnosis and management. 
Among these lesions are osteomyelitis, osteoradionecrosis, alveolar osteitis, sinusitis, 
fibro-osseous lesions, chronic sclerosing osteomyelitis and oral ulceration and bone 
sequestration (OUBS) [49, 67, 68]. 
Treatment  
There is an ongoing scientific debate about the optimal treatment of MRONJ. The 
early recommendations favored the non-surgical treatment [69]. Based on the current 
experience and knowledge, conservative management of MRONJ can be considered 
in stage 0 and 1 lesions in patients with limited life expectancy, while surgical 
treatment is a reasonable option in all stages especially in stage 2 and 3 lesions. 
Several studies highlighted the efficacy of surgery in achieving complete healing, 
namely complete mucosal coverage [70-72]. 
The guidelines of the German Society of Oral and Maxillofacial Surgery allow 
surgical treatment of MRONJ in all stages (0-3) [73]. The current AAOMS 
recommendations (2014-update) emphasize the non-surgical treatment for stage 0 and 
1 and limit surgery to the more advanced stages [49]. During the last few years, 
numerous studies have reported good results with surgical treatment of MRONJ [70, 
71, 74-76]. Non-surgical management is mostly based on antibacterial mouth rinses 
and long courses of antibiotics sometimes combined with debridement of superficial 
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necrotic bone with the objective of minimizing symptoms rather than curing MRONJ. 
Nicolatou-Galitis et al. reported mucosal healing after a mean of 17.5 months of 
conservative therapy in only 23% of patients [77].  On the other hand, non-surgical 
treatment can be reasonable in patients with limited life expectancy and poor general 
status. Nowadays, the general survival rates of malignancy patients have increased 
thanks to the remarkable innovations in anticancer therapies. Therefore, a precise 
evaluation of the patient’s overall health and performance status is very essential in 
regards to the clinical decision-making in MRONJ treatment.  
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OBJECTIVES OF THE THESIS  
The main objectives of this thesis were to: 
1) To perform a systematic review to identify the effect of ARDs (Type, time of 
use prior to the onset of MRONJ, and way of administration) on MRONJ 
onset in osteoporotic patients. It aims also to determine the associated 
potential risk factors, demographic and clinical characteristics in this particular 
group of patients. 
2) To understand the clinical course of the newly reported type of MRONJ, 
DRONJ, and to determine its response to treatment. For that aim, 
characteristics of ARDs, demographics, systemic factors, local factors, 
treatment modalities, and their outcomes were analyzed retrospectively. Few 
case series of DRONJ have been reported so far. Therefore, this case series, 
which is the largest so far, can aid in understanding the course of DRONJ. 
Another aim was to detect the effect of BP intake prior to denosumab on the 
clinical characteristics and treatment outcomes of DRONJ. 
3) To perform a review of the literature aiming to elucidate the different types of 
inflammatory diseases of the jawbones, mainly MRONJ, osteomyelitis and 
osteoradionecrosis and to compare them to osteomyelitis of the other parts of 
the skeleton. This review aids in improving the understanding of these 
diseases and can subsequently help to establish the correct diagnosis and 
management. 
4) To retrospectively evaluate the outcomes of surgical treatment of upper jaw 
MRONJ using single-layer closure (mucoperiosteal flap) and double-layer 
closure (mucoperiosteal flap followed by buccal fat pad flap). Another aim is to 
find out the outcomes of using obturator prostheses for the more extensive upper 
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jaw lesions, which cannot be reconstructed surgically. Few similar studies have 
been reported, with this study being the largest so far.  The management of 
maxillary MRONJ is particularly challenging due to the limited alveolar bone 
mass and proximity to the maxillary sinus. Therefore, it is crucial to identify the 
proper treatment of this entity of MRONJ. 
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Purpose: Osteonecrosis of the jaw has been recently reported in patients receiving denosumab for the
treatment of metastatic bone disease and osteoporosis. It is essential to investigate this disease as a new
osteonecrosis entity in order to recognize its optimal management strategies.
Materials and Methods: A total of 63 cases of denosumab-related osteonecrosis of the jaw (DRONJ)
diagnosed at two clinical centres were retrospectively reviewed. Demographics, comorbidities, anti-
resorptive medication use, local preceding event, location, DRONJ stage, treatment and treatment out-
comes were analyzed.
Results: In all, 69 MRONJ lesions in 63 patients were diagnosed. The mean patient age was 70 ± 9 years.
Denosumab was the only received antiresorptive medication in 50.8% of the patients. Discontinuation of
denosumab prior to treatment was recorded for 66.7% of the patients, with a mean period of 6 ± 3.4
months. Stage 2 was the most common stage of the disease (71%). The lesions were predominantly
located in the mandible (63.5%). The most common preceding local event was extraction (55.6%). Surgical
treatment was performed in 95.7% of the cases, while purely conservative treatment was performed in
4.3%. DRONJ healed after surgical treatment in 71.7% of the treated lesions. Complete mucosal healing
was achieved in 77.2% of the lesions treated with fluorescence-guided surgery (17/22). Clinical charac-
teristics and treatment outcomes were not significantly different between patients with and without
previous intake of bisphosphonates.
Conclusion: DRONJ is more prevalent at extraction and local infection sites in cancer patients. Within the
limitation of this study, surgical treatment, particularly fluorescence-guided surgery, appears to be
effective for the management of DRONJ. The prior use of bisphosphonates does not seem to affect
severity nor the treatment success rate of DRONJ.
© 2018 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights
reserved.
1. Introduction
Bone metastasis is not uncommon in patients with advanced
cancer stages. It has been shown in 70e80% of patients with breast
or prostate cancer and 30e40% of patients with lung cancer or
other solid tumors (Lipton et al., 2012). Skeletal-related events
(SREs) that comprise pathologic fracture, spinal cord compression,
hypercalcemia, and radiation or surgery to bone are prevalent in
patients with bone metastasis (Oster et al., 2013). The cumulative
incidence of SREs at 2 years is 54.2% in patients with breast cancer,
41.9% in patients with prostate cancer, and 47.7% in patients with
lung cancer (Oster et al., 2013). SREs can negatively affect patients'
quality of life and result in bone pain, fractures, bladder and bowel
disturbances, anxiety, depression, and increased mortality (Oster
et al., 2013). At present, antiresorptive medications, including
bisphosphonates and denosumab, are the current treatment
* Corresponding author. Department of Oral and Maxillofacial Surgery, Ludwig-
Maximilians-University, Lindwurmstraße 2a, Munich 80337, Germany. Fax: þ49
89 51604746.
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options to prevent SREs. The results of three randomized trials
showed that denosumab is superior to bisphosphonates in regard
to SREs treatment and prevention (Stopeck et al., 2010; Fizazi et al.,
2011; Henry et al., 2014). Furthermore, antiresorptive medications
are also used for osteoporosis and are proven to reduce bone
turnover markers, improve bone mineral density, decrease fracture
risk, and improve the quality of life (McClung et al., 2013).
Thefirst caseseries ofbisphosphonate-relatedosteonecrosisof the
jaw (BRONJ) were published in the early 2000s and followed by
hundreds of reports, which raised the awareness of this potential
complication (Marx, 2003; Bagan et al., 2016). Denosumab was also
shown to be related to jaw osteonecrosis in both cancer and osteo-
porosispatients (Olateet al., 2014;Ruggieroetal., 2014). Initially, cases
of denosumab-related osteonecrosis of the jaw (DRONJ) were re-
ported during randomized clinical trials for the treatment of cancer
and osteoporosis (Fizazi et al., 2009, 2011; Aghaloo et al., 2010; Henry
et al., 2011; Lipton et al., 2012; Malan et al., 2012; Saad et al., 2012;
Bone et al., 2013; Qi et al., 2014; Papapoulos et al., 2015; Sugimoto
et al., 2015; Stopeck et al., 2016). As denosumab was approved and
came into use, more cases were reported (Diz et al., 2012; Aghaloo
et al., 2014; O'Halloran et al., 2014; Olate et al., 2014; You et al.,
2015; Owosho et al., 2016; Qaisi et al., 2016). The risk of DRONJ in
osteoporosispatients treatedwithdenosumab isestimated tobe from
0.01% to 0.03%, and in cancer patients treated with denosumab to be
from 1% to 2% (Aljohani et al., 2017). This incidence is comparable to
that of BRONJ. In a combined analysis of three phase III trials in pa-
tientswithmetastatic bonedisease receiving antiresorptive therapies
J, incidence of ONJ was higher in denosumab group in comparison to
the bisphosphonates group, 1.8% and 1.3% respectively (Saad et al.,
2012). However, the cumulative incidence of ONJ was not signifi-
cantly different between the treatment groups. In order to accom-
modate osteonecrosis cases appearing in relation to denosumab and
antiangiogenic agents, the American Association of Oral and Maxil-
lofacial Surgeons (AAOMS) changed the name of BRONJ to
medication-related osteonecrosis of the jaw (MRONJ) (Ruggiero et al.,
2014).
Although the reported cases of DRONJ are limited, DRONJ seems
to share several clinical characteristics with BRONJ. Several risk
factors appear to be related to their development, such as local
infection; mainly periodontitis; dental extraction, dentoalveolar
surgery and denture sore spots. Their incidence may increase with
chronic corticosteroid therapy, diabetes mellitus, immunosup-
pressants and chemotherapy (Ruggiero et al., 2014). While favor-
able treatment outcomes for the surgical treatment in patients
suffering from BRONJ have been reported, the information
regarding treatment outcomes of DRONJ is still sparse. Indeed,
there are limited data regarding the risk factors and natural history
of DRONJ as well as management strategies and respective
outcomes.
Here we describe the largest clinical series so far of DRONJ pa-
tients from two German academic Maxillofacial Surgery de-
partments. The objective of this study is to analyze the
antiresorptive medication characteristics, demographics, related
comorbidities, local preceding events, treatment strategies, and
treatment outcomes of DRONJ. Patients with prior intake of
bisphosphonates were included in this series in order to compare
bisphosphonate-naive and nonebisphosphonate-naive patients in
regards to the clinical characteristics and treatment outcomes.
2. Materials and methods
2.1. Study design
A retrospective medical chart review was carried out at two
German institutions: the Department of Oral and Maxillofacial
Surgery, Ludwig-Maximilians-University, Munich, and the Depart-
ment of Oral and Maxillofacial Surgery and University Medical
Center Hamburg-Eppendorf, Hamburg. Institutional Review Board
approval was obtained at both participating institutions (083-11,
Ludwig-Maximilians-University and PV3806, University Medical
Center Hamburg-Eppendorf). All patients diagnosed and treated for
DRONJ between July 2011 and April 2017 were identified.
This study included all patients diagnosed with DRONJ based on
the following criteria: 1) MRONJ diagnosis based on AAOMS criteria
(Ruggiero et al., 2014) in patients receiving denosumab with or
without history of bisphosphonates intake; and 2) a minimum
period of 3 months between the last administration of
bisphosphonates and DRONJ onset.
The exclusion criteriawere: a history of head and neck radiation,
obvious metastasis to jaw bones and a history of bisphosphonates
within the 3 months preceding the onset of DRONJ. According to
AAOMS, MRONJ can be diagnosed if antiresorptive or anti-
angiogenic therapy was followed by exposed bone or bone that can
be probed through an intraoral or extraoral fistula in the maxillo-
facial region that has persisted for more than 8 weeks with no
history of radiation therapy or obvious metastatic disease to the
jaws (Ruggiero et al., 2014).
2.2. Data extraction
A total of 63 patients were identified and fulfilled the entry
criteria. The following variables were recorded and reviewed:
demographic data, the main indication of denosumab admin-
istration, comorbidities (diabetes mellitus, cardiovascular dis-
ease, allergy, autoimmune disease, hypothyroidism,
corticosteroids and chemotherapy), number of denosumab
doses, preceding local event, time between local event and
MRONJ onset, clinical stage at initial presentation and location
of DRONJ, treatment modalities (if any), follow-up period and
outcomes were recorded and reviewed. The lesions were clas-
sified into 4 stages (0e3) according to the last position paper of
the AAOMS (Ruggiero et al., 2014).
2.3. Data analysis
Descriptive statistics were used to report patient characteris-
tics. Categorical variables such as MRONJ location, treatment
modality and treatment outcome were investigated by the Fisher
exact test. Continuous variables such as number of denosumab
doses were investigated using the Student t test. A p value of less
than 0.05 was considered statistically significant. All statistical
analyses were performed with SPSS software (SPSS Inc., Chicago,
IL, USA).
3. Results
3.1. Patients
In all, 69MRONJ lesions in 63 patients were identified. The average
age was 70 ± 9 years (Table 1). Demographics including gender, indi-
cation of denosumab use and comorbidities are presented in Table 2.
3.2. Antiresorptive medications
The number of denosumab doses was recorded for 47 patients
with an average of 16.4 ± 12.6 doses. Table 3 presents denosumab
types and doses used and the characteristics of previous
bisphosphonate use.
S. Aljohani et al. / Journal of Cranio-Maxillo-Facial Surgery xxx (2018) 1e112
Please cite this article in press as: Aljohani S, et al., Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series,
Journal of Cranio-Maxillo-Facial Surgery (2018), https://doi.org/10.1016/j.jcms.2018.05.046
 
26  
3.3. Location of DRONJ
The mandible was affected in 40 cases (63.5%), the maxilla in 17
cases (27%) and both jaws in 6 cases (9.5%). MRONJ was located in
the molar area in 20 patients (31.7%); in both premolar and molar
area in 16 cases (25.4%); in the anterior, premolar and molar areas
in 10 cases (15.9%); the anterior area in 6 cases (9.5%); in both
anterior and premolar areas in 4 patients (6.3%); premolar area in 3
cases (4.8%) and in anterior and molar area in 3 cases (4.8%); and
involving the hard palate in one case (1.6%). In this study, stage 2
was the most common (n ¼ 49, 71%). Stage 3 MRONJ was identified
in 10 lesions (14.5%), stage 1 MRONJ in 7 lesions (10.1%) and stage
0 MRONJ in 3 lesions (4.3%).
3.4. Potential local risk factors
Tooth extraction (mainly due to local infection), either as the
only preceding event or in combination with other local factors,
was recorded for 55.6% of the cases (n ¼ 35) (Table 4). The mean
period between the preceding local event and start of signs and
symptoms was recorded for 32 cases and was 2.6 ± 1.6 months.
3.5. Treatment strategies
Surgical treatment was performed in 66 lesions in 60 patients
(95.7%), of them 27 lesions underwent fluorescence-guided surgery
(41%), 38 lesions were treated with conventional surgery (57.5%),
and one patient underwent extraction and curettage (1.5%)
(Table 5). Surgical treatment included antibiotic treatment, com-
plete surgical removal of necrotic bone, smoothening of sharp bony
edges and plastic coverage (Fig. 1 ael and Fig. 2aee). For some
patients who received operative treatment, prior conservative
treatment had been tried without success. Purely conservative
treatment was performed for 3 lesions (4.3%). The mean of follow-
up period was 10.4 ± 9.5 months (ranging from 3 to 48 months). Of
the cohort, 66.7% underwent denosumab holiday prior to the sur-
gical treatment or the conservative therapy. For conservatively
treated patients, denosumab were discontinued for a mean period
of 10 ± 7 months, while for surgically treated patients, denosumab
was discontinued for a mean period of 5.6 ± 3 months.
3.6. Treatment outcomes
Eleven patients (13 lesions) were lost to follow-up. Complete
healing was defined as complete mucosal coverage with absence of
MRONJ signs and symptoms. Partial healing is defined as
improvement of the signs and symptoms without complete reso-
lution of the lesion. A total of 53 lesions treated surgically were
followed up. Surgical treatment has led to healing in 38 lesions
(71.7%), non-healing in 9 cases (17%), and partial healing in 6 sites
(11.3%).
A total of 22 lesions treated with fluorescence-guided bone
resection were followed up. Complete mucosal healing was ob-
tained in 77.3% of the patients treated by fluorescence-guided bone
surgery (17/22) (Fig. 2feg). One lesion had partial healing (4.5%),
and 4 lesions (18.2%) did not heal.
In all, 31 lesions managed with conventional surgery were fol-
lowed up. Complete mucosal healing was obtained in 67.7% of the
patients treated with this surgical technique (21/31). Five lesions
(16.1%) failed to heal, while 5 (16.1%) healed partially. The lesion
treated with extraction and curettage of the bony socket healed
completely.
Two of the 3 cases treated conservatively healed completely,
while 1 case (33.3%) failed to heal. Treatment outcome has no
statistically significant relationship with chemotherapy, DRONJ
stage and denosumab cessation.
3.7. Impact of previous use of bisphosphonates
A total of 34 lesions in 31 patients with previous bisphospho-
nates were detected. No significant difference in the demographics,
clinical characteristics and DRONJ stage of bisphosphonate-naïve
patients (n ¼ 32, 50.8%) and those who had had bisphosphonates
before (n ¼ 31, 49.2%) (Table 6). The average number of denosumab
doses was slightly less, but still insignificant, in patients who had
received bisphosphonates than in patients without a bisphospho-
nate history (15.3 ± 14.6 and 17.5 ± 10.6 doses, respectively).
Moreover, statistical significance between prior bisphosphonate
therapy and outcomes of treatment was not observed (p ¼ 0.654).
4. Discussion
Literature searches did not reveal more extensive case series
describing the clinical presentation and management of DRONJ. A
total of 63 DRONJ patients were identified, 32 of them had deno-
sumab as the only received antiresorptivemedication. The available
studies are mostly case reports and a few small case series of less
than 20 patients. Within the limitations of a retrospective chart
review, we aim in the present series to elucidate the clinical char-
acteristics, potential risk factors, treatment modalities and treat-
ment outcomes in DRONJ patients. Another aim is to find the effect
of prior administration of bisphosphonates on DRONJ risk, severity
and treatment outcomes. Furthermore, the time between the local
event, if any, and MRONJ onset were analyzed to further charac-
terize the clinical course of the disease.
In the present study, females (58%) were affected slightly more
thanmales. This is comparable to the findings of de Oliveiro and his
colleagues based on a review of 17 reported DRONJ cases (de
Oliveira et al., 2016). The same review reported osteoporosis and
osteopenia as the most common primary disease (47%) and only
5.9% had breast cancer, while almost half of our cohort was affected
by breast cancer (42.9%) and only 14.3% had osteoporosis. In
agreement with our findings, a recent case series of 17 DRONJ pa-
tients reported that 52.9% of the cases had breast cancer (Hoefert
et al., 2017). In general, as estimated by AAOMS, the risk of
MRONJ for metastatic cancer patients treated with denosumab is
0.7%e1.9% (Ruggiero et al., 2014). On the other hand, the risk in
osteoporosis patients treated with either zoledronate or denosu-
mab is much lower (0.017%e0.04%) (Ruggiero et al., 2014).
Potential systemic risk factors of MRONJ, including comorbid-
ities and concomitant medications, have been evaluated. However,
evidence-based findings remain sparse. Saad et al. found that there
was no association between anemia, diabetes mellitus, or received
chemotherapy and MRONJ. However, the same study reported a
slightly greater number of MRONJ among the patients using sys-
temic corticosteroids (Saad et al., 2012). Corticosteroids are known
to delay wound healing and, unsurprisingly, could potentially
contribute to the development of MRONJ. In our study, 11.1% of the
patients received long-term corticosteroid therapy. Antiangiogenic
agents can suppress vascular regeneration and subsequently might
promote ONJ. In three prospective trials, antiangeogenic medica-
tions were associated with MRONJ (15.7%) more than corticoste-
roids intake (Saad et al., 2012). Several cases of MRONJ in relation to
antiangiogenic medications, even with no concomitant intake of
antiresorptive medications, were reported (Estilo et al., 2008; Disel
et al., 2012; Hopp et al., 2012; Santos-Silva et al., 2013). On the other
hand, an analysis of three large prospective trials in advanced
breast cancer in 3,560 patients receiving bevacizumab with or
without bisphosphonates therapy found that bevacizumab use did
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not increase BRONJ incidence (0.9e2.4%) (Guarneri et al., 2010).
Nevertheless, the same analysis estimated ONJ incidence of
0.3e0.4% in those who received bevacizumab without bisphosph-
onate therapy. These findings indicate that antiangeogenic agents
could potentially contribute to ONJ risk. In our cohort, 7.9% of the
cases had received antiangiogenic medications. According to a
meta-analysis of events reported in seven denosumab clinical trials,
chemotherapy was found to promote DRONJ development
(Boquete-Castro et al., 2016). In line with this, 75.9% of our cohort
had received chemotherapy. Diabetes mellitus was reported in only
Table 1
Summary of the clinical characteristics.
Case Age Sex Primary disease Dmab dose Number of doses Hx of BPs Comorbidities Local factors
1 59 F OP 60 mg/6 months 1 Yes Allergy Extr
2 68 F OP 60 mg/6 months 2 No RA, allergy, hypothyrodism Extr, P, PI
3 67 M Prostate ca 120 mg/4 weeks … Yes CS, DM II, CVD Scaling and RP, P
4 63 M Prostate ca 120 mg/4 weeks … Yes RA, CS Extr
5 75 F OP 60 mg/6 months … No HT, COPD, CVD Extr
6 66 M Prostate ca 120 mg/4 weeks 18 No HT, hypothyrodism Extr
7 66 F Brest ca 120 mg/4 weeks 22 No Allergy, DM II Local trauma
8 76 F Lung ca 120 mg/4 weeks 3 Yes HT Extr
9 56 F Breast ca 120 mg/4 weeks 7 Yes Allergy Extr, local trauma
10 69 M Prostate ca 120 mg/4 weeks 20 Yes HT Extr
11 70 M Prostate ca 120 mg/4 weeks … Yes CVD Extr
12 67 F Breast ca 120 mg/4 weeks 7 No OP, CS Extr
13 76 F OP 60 mg/6 months 6 Yes RA, CS P
14 78 M Prostate ca 120 mg/4 weeks 11 No DM II, CS Extr
15 80 F Breast ca 120 mg/4 weeks 29 No HT, RA P
16 65 M Prostate ca 120 mg/4 weeks 36 Yes Allergy, CS Extr
17 58 F Breast ca 120 mg/4 weeks 35 Yes Allergy None
18 63 F Melanoma 120 mg/4 weeks … No HT, RA, allergy, hypothyrodism Ext
19 56 F Breast ca 120 mg/4 weeks 5 Yes CVD, allergy Ext
20 74 M Thyroid ca 120 mg/4 weeks 8 Yes COPD, allergy, Asthma P
21 50 F Breast ca 120 mg/4 weeks 24 No CVD Extr
22 74 F Breast ca 120 mg/4 weeks 45 Yes HT, allergy None
23 76 F Breast ca 120 mg/4 weeks 18 No None Extr, local trauma
24 64 F Breast ca 120 mg/4 weeks 8 Yes OP, allergy Extr
25 83 F Breast ca 120 mg/4 weeks 2 Yes DM II, allergy Local trauma
26 72 M Prostate ca 120 mg/4 weeks 36 No DM II, HT None
27 52 F Breast ca 120 mg/4 weeks 24 No Allergy None
28 79 F Breast ca 120 mg/4 weeks 11 No DM II Extr, P
29 67 M Breast ca 120 mg/4 weeks 10 No Hypothyrodism, allergy Extr, local trauma
30 78 M OP 60 mg/6 months 6 Yes HT, hyperthyroidism Local trauma
31 71 M Breast ca 120 mg/4 weeks … No CVD, hypertension None
32 74 F Kidney ca 120 mg/4 weeks 6 Yes HT, RA, CS, Retuximab Local trauma
33 72 F OP 60 mg/6 months 1 Yes CVD, allergy P
34 67 F Breast ca 120 mg/4 weeks 30 No HT None
35 78 M Prostate ca 120 mg/4 weeks 31 Yes DM II Extr, P
36 82 F OP 60 mg/6 months 6 No CVD, CRD Extr, P
37 65 M Prostate ca 120 mg/4 weeks … Yes COPD, DM II P
38 66 M MM 120 mg/4 weeks … Yes Hypothyrodism, HT, CVD Extr
39 80 F Breast ca 60 mg/3 months 3 Yes RA, CS Extr
40 48 F Breast ca 120 mg/4 weeks 30 No None Extr
41 75 F Breast ca 120 mg/4 weeks 5 Yes CVD, allergy, hypothyrodism None
42 71 F Breast ca 120 mg/4 weeks 22 Yes OP None
43 74 F Breast ca 120 mg/4 weeks 20 Yes CVD, allergy P
44 60 F Breast ca 120 mg/4 weeks 24 No None Extr
45 67 M Prostate ca 120 mg/4 weeks 22 No None Extr
46 74 F Breast ca 120 mg/4 weeks … Yes Renal insufficiency II None
47 86 F Breast ca 120 mg/4 weeks … Yes None Extr
48 84 F MM 120 mg/2 months … No DM II Extr
49 73 F OP 60 mg/6 months … Yes HT Extr
50 52 M Kidney ca 120 mg/4 weeks 24 No Unilateral nephrectomie Extr
51 74 F OP 60 mg/6 months 1 No COPD, HT Extr
52 55 F Breast ca 120 mg/4 weeks 48 Yes None Extr
53 56 M Prostate ca 120 mg/4 weeks … No HT None
54 74 M Prostate ca 120 mg/4 weeks 6 No HT None
55 73 M Kidney ca 120 mg/4 weeks 12 No None Site of implant
56 72 M Thyroid Ca 120 mg/4 weeks 36 No HT PI
57 86 M Prostate ca 120 mg/2 months 10 Yes HT, history of kidney cancer Site of implant
58 77 M Prostate ca 120 mg/4 weeks … No HT None
59 73 M Prostate ca 120 mg/4 weeks 24 Yes None Extr
60 83 M Prostate ca 120 mg/3 months … No DM II None
61 82 F Breast ca 60 mg/6 months 5 No COPD, CVD, HT Ridge augmentation
62 69 M Kidney ca 120 mg/4 weeks 12 No CRD, HT Extr
63 75 F Breast ca 120 mg/4 weeks … No HT Extr
Dmab: denosumab, Hx: history, BPs: bisphosphonates, …: missing data, M: male, F: female, OP: osteoporosis, MM: multiple myeloma, HT: hypertension, RA: rheumatoid
arthritis, DM II: type 2 diabetes mellitus, CO: corticosteroids, CVD: coronary vascular disease, COPD: coronary obstructive pulmonary disease, CRD: chronic renal disease, Extr:
extraction, P: periodontitis, PI: peri-implantitis, RP: root planing.
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17.6% of the reported DRONJ cases (de Oliveira et al., 2016), which
does not differ greatly from our findings of 14.5%.
Ironically, the pathogenesis of MRONJ has not yet been fully
elucidated, despite the large body of literature available. Bone
remodeling is very crucial tomaintain a healthy osseous tissue. This
is particularly essential in jawbones in order to remove the micro-
damage resulting from masticatory forces and dental infection.
However, this important physiological process can be strongly
derailed by antiresorptive medications, leading to accumulation of
necrotic tissue, and thereby can result in osteonecrosis of jawbones.
This might explain the unique localization of MRONJ almost
exclusively in the jawbones. The mandible, with its dense bone and
single blood supply, is more commonly affected with MRONJ than
themaxilla, in a 2:1 ratio (Ruggiero et al., 2014; Hoefert et al., 2017).
The same ratio was identified for DRONJ localization in this study.
The involvement of the two strong bone-targeted osteoclast in-
hibitors in MRONJ onset strongly suggests the osteoclast suppres-
sion, and thereby low bone turnover, as a main causative factor.
However this suppression of bone remodeling is not limited to the
jaws and could show also in the other skeletal parts, despite the fact
that no cases of necrosis there have been reported. It is important to
bear in mind that other medications with less potent antiresorptive
effects such as oestrogen and calcitonin are not associated with ONJ
(Yamashita and McCauley, 2012). Therefore, suppressed bone
remodeling does not seem to be satisfactory in verifying the exact
pathogenesis of MRONJ. Scintigraphy of the maxilla and mandible
did not overly change in comparisonwith that of other bones in the
body, either by bisphosphonates or denosumab in cancer patients
(Ristow et al., 2014). All of these findings indicate that there are still
missing pieces in the MRONJ pathogenesis puzzle.
Several risk factors can increase the risk of developing MRONJ.
Potential local risk factors such as extraction, dento-alveolar
surgery, periodontitis and trauma from ill-fitted prostheses
were reported. An integrated analysis from three blinded active-
controlled phase III trials in cancer patients with bone metasta-
ses receiving either zoledronate or denosumab showed that 61.8%
of MRONJ patients had tooth extraction prior to its onset (Saad
et al., 2012). Tooth extraction was related to 66% and 77% of
DRONJ cases in a systematic analysis of events reported in deno-
sumab clinical trials (Boquete-Castro et al., 2016). In agreement
with other authors, dental extraction was found to be the most
common preceding event to DRONJ onset (55.6%). It is noteworthy
that the indication for extraction in most of the cases was local
infection. Furthermore, local infection, namely periodontitis as
well as peri-implantitis, were detected at sites of necrosis in at
least 19% of our cases. The role of infection in BRONJ development
was highlighted by the infection-driven MRONJ pathogenesis
theory (Otto et al., 2010a, 2010b). Local infection can result in a
remarkable increase in local acidity. This can increase the local
release of bisphosphonates and lead to suppression of all the cells
in the bony tissue, including osteoclasts, osteoblasts, fibroblasts,
mesenchymal stem cells and angiogenic cells, and thereby can
maximize the antiresorptive effects (Otto et al., 2015). The
resulting bone damage can subsequently fail to resolve, and
osteonecrosis can develop. Our results suggest that local infection
might play a role in DRONJ pathogenesis as in BRONJ pathogenesis
and, based on that, preventive dental treatment and meticulous
oral hygiene before and during denosumab treatment are highly
recommended.
Most of the adverse events of denosumab treatment, including
DRONJ, were observed with the dose of 120 mg (Boquete-Castro
et al., 2016; de Oliveira et al., 2016; Hoefert et al., 2017). This is
similar to the observation of increased risk of BRONJ in relation to
Table 2
Demographics and comorbidities.
n (%)
Gender
Female 37 (59%)
Male 26 (41%)
Indication for denosumab use
Breast cancer 27 (42.9%)
Prostate cancer 17 (27%)
Osteoporosis 9 (14.3%)
Kidney cancer 4 (6.3%)
Multiple myeloma 2 (3.2%)
Thyroid cancer 2 (3.2%)
Lung cancer 1 (1.6%)
Melanoma 1 (1.6%)
Comorbidities
Type 2 diabetes mellitus 9 (14.5%)
Rheumatoid arthritis
Corticosteroids
6 (9.5%)
7 (11%)
Allergy 16 (25.4%)
Hypertension 11 (17.5%)
Hypothyrodism 22 (35%)
Asthma 7 (11%)
Osteoporosis 1 (1.6%)
History of kidney cancer 1 (1.6%)
Chronic obstructive pulmonary disease 1 (1.6%)
Chemotherapy 41 (76%)
Long-term steroid use 7 (11%)
Antiangeogenic medications 5 (7.9%)
Rituximab 1 (1.6%)
Table 3
Antiresorptive medication characteristics.
n (%)
History of bisphosphonate use
No 32 (50.8%)
Yes (mean duration was 36.9 ± 23 months) 31 (49.2%)
Type of bisphosphonates
Zoledronate 21 (67.5%)
Alendronate 2 (6.5%)
Pamidronate 2 (6.5%)
Ibandronate 2 (6.5%)
Zoledronate and pamidronate 4 (12.9%)
Unknown 2 (6.5%)
Type denosumab
XGEVA® 52 (82.5%)
Prolia® 11 (17.4%)
Denosumab dose
120 mg every 4 weeks 49 (77.8%)
60 mg every 6 months 10 (15.9%)
120 mg every 2 months 2 (3.2%)
120 mg every 3 months 1 (1.6%)
60 mg every 3 months 1 (1.6%)
Denosumab holiday
Yes (an average of 6 ± 3.4 months) 42 (66.7%)
No 4 (6.3%)
Unknown 17 (27%)
Table 4
Preceding local event.
Local event n (%)
Extraction only 28 (44.4%)
Periodontitis 6 (9.5%)
Local trauma from ill-fitted denture 4 (6.3%)
Extraction and trauma from ill-fitted denture 3 (4.8%)
Extraction and periodontitis 3 (4.8%)
Extraction, periodontitis and peri-implantititis 1 (1.6%)
Implant placement 2 (3.2%)
Peri-implantitis 1 (1.6%)
Ridge augmentation 1 (1.6%)
Scaling and root planing due to periodontitis 1 (1.6%)
Unknown 13 (20.6%)
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potent intravenous bisphosphonates in oncological dosing
(Ruggiero et al., 2014). Denosumab is a very potent antiresorptive
medication that can induce dose-dependent osteoclast inhibition
just few hours after its subcutaneous injection (Anastasilakis et al.,
2012). This high dose of denosumab is used mostly for oncological
indications, while the lower dose of 60 mg is indicated for osteo-
penia and osteoporosis. Increased denosumab concentration
combined with the other comorbidities associated with cancer;
such as the cancer itself, chemotherapy and antiangeogenic agents;
can increase the risk of MRONJ in oncology patients. In agreement
with other authors, the majority of DRONJ cases in this study
(82.5%) were associated with the dose of 120 mg used for cancer
patients (Khan et al., 2015; Boquete-Castro et al., 2016; de Souza
Povoa et al., 2016; Favia et al., 2016; Owosho et al., 2016).
Table 5
Location, stages, treatment and treatment outcomes.
Case Site Stage Drug holiday Duration of drug holiday (months) Treatment Follow-up (months) Treatment outcome
1 mandible 2 Yes 6 Surgical 48 Healing
2 mandible 3 Yes 6 Surgical 16 Healing
3 maxilla 2 Yes 6 Surgical None
4 mandible 2 Yes 4 Surgical 39 Partial healing
5 mandible 2, 2a Yes 6 Surgical 7 No healing
6 maxilla 2 Unknown Surgical None
7 mandible 0 Yes 18 Non-surgical 29 Healing
8 maxilla 2 Yes 3 Surgical 13 Healing
9 mandible 2 Yes 6 Surgical 4 Healing
10 mandible 2 Yes 6 Non-surgical 12 Healing
11 maxilla 2 Yes 6 Surgical 7 Healing
12 mandible 2 Yes 6 Surgical 2 Healing
13 mandible 0 Yes 6 Surgical 2 Healing
14 mandible 2 Yes 4 Surgical 5 No healing
15 maxilla 2 Yes 3 Surgical 24 Healing
16 mandible 2 Yes 6 Surgical None
17 mandible 2 Yes 6 Surgical None
18 mandible 1 Yes 6 Surgical 1 Healing
19 both 2, 2a Yes 6 Surgical 12 No healing
20 mandible 1 Yes 13 Surgical 2 Healing
21 mandible 2 Yes 6 Surgical 1 No healing
22 mandible 1 Yes 4 Surgical 6 Healing
23 maxilla 3 Yes 6 Surgical 1 Healing
24 maxilla 3 No Surgical 12 Healing
25 mandible 2 Yes 8 Surgical 6 Healing
26 maxilla 2 Yes 2 Surgical 6 Healing
27 mandible 2 Yes 6 Surgical 4 Healing
28 mandible 2 Yes 3 Surgical None
29 mandible 2 Yes 6 Surgical 2 Healing
30 mandible 2 Yes 6 Surgical 6 Healing
31 mandible 2 Yes 2 Surgical 8 Healing
32 mandible 1 Yes 6 Non-surgical 10 No healing
33 mandible 2 Yes 6 Surgical 6 Healing
34 mandible 1 Yes 3 Surgical None
35 both 2, 2a Yes 2 Surgical None
36 mandible 2 Yes 7 Surgical 3 Healing
37 both 0, 2a No Surgical None
38 mandible 2 Yes 3 Surgical 20 Partial healing
39 maxilla 1 Yes 6 Surgical None
40 mandible 2 Yes 6 Surgical None
41 maxilla 2 Yes 18 Surgical None
42 maxilla 1, 3a Yes 6 Surgical 3 Healing
43 maxilla 3 Yes 6 Surgical 3 Healing
44 mandible 2 Unknown Surgical 17 Partial healing
45 mandible 2 Unknown Surgical 15 Healing
46 mandible 2 Unknown Surgical 7 Healing
47 mandible 2 Unknown Surgical 17 Healing
48 maxilla 3 Unknown Surgical 21 Partial healing
49 mandible 2 Unknown Surgical 1 Healing
50 mandible 2 Unknown Surgical 5 Healing
51 mandible 2 Unknown Surgical 3 Healing
52 mandible 2 Unknown Surgical 12 No healing
53 maxilla 2 Unknown Surgical 4 Healing
54 mandible 2 No Surgical 8 No healing
55 mandible 2 Unknown Surgical 20 Partial healing
56 mandible 2 Yes 2 Surgical 6 Partial healing
57 maxilla 3 Unknown Surgical 1 Healing
58 maxilla 3 Unknown Surgical 2 Healing
59 mandible 2 Yes 4 Surgical 20 Healing
60 maxilla 3 No Surgical 5 Healing
61 mandible 2, 3a Unknown Surgical 21 Healing
62 mandible 2 Unknown Surgical 17 Healing
63 mandible 2 Unknown Surgical 8 No healing
a Two MRONJ lesions in the same patient.
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Understanding of the effect of denosumab doses number on
DRONJ onset is essential for risk assessment. However, the data in
this area remain sparse. It is still unknownwhether the cumulative
dose of denosumab has an influence on ONJ development compa-
rable to that of bisphosphonates. Owosho et al. reported develop-
ment of DRONJ after an average of 15 doses of denosumab. A recent
case series of 17 patients reported DRONJ onset after 14.1 denosu-
mab doses (Hoefert et al., 2017). An almost-similar finding was
noted in our case series (16.4 doses). On the other hand, Rachner
et al. reported DRONJ in osteoporosis patients after only a single
dose of 60 mg denosumab (Rachner et al., 2013); however, this
patient had been previously taking alendronate for 3 years. In this
cohort, patients with previous use of bisphosphonates developed
DRONJ after a slightly lower number of denosumab doses than
those without (15.3 doses versus 17.5 doses).
Denosumab has a shorter half-life of 26 days and, unlike
bisphosphonates, does not accumulate in bone. Subsequently,
denosumab antiresorptive effects are reversible upon treatment
cessation. Based on these pharmacological characteristics, some re-
searchers have suggested favorable effects of stopping denosumab
after DRONJ onset or prior to dental extraction on the healing and
prevention of DRONJ lesions (O'Halloran et al., 2014). The data
regarding this effect of DRONJ holiday are sparse. Spontaneous
healing upon denosumab discontinuationwas reported (Taylor et al.,
2010; Malan et al., 2012; Ohga et al., 2015). Saad et al. indicated that
ONJ lesions associated with denosumab had a more rapid healing
(40%) than those associated with zoledronate (29%) (Saad et al.,
2012). In addition, discontinuation of denosumab but not zoledro-
nate was reported to promote MRONJ healing in a murine model (de
Molon et al., 2015). On the other hand, two recent DRONJ case series
reported no advantage of denosumab holiday either in promoting
spontaneous healing in those cases treated conservatively or in
improving surgical treatment outcomes (Owosho et al., 2016;
Hoefert et al., 2017). In agreement with these studies, we did not
see an association between a denosumab holiday and DRONJ healing.
However, a positive effect of denosumab cessation on DRONJ can be
assumed, given its short half-life. It is very important to know that
pausing denosumab even for short intervals can result in remarkable
rebound in bone remodeling and bone mineral density (BMD) and
might lead to increased fracture risk (McClung, 2016).
The early management recommendations of BRONJ favored the
conservative treatment over surgical intervention. Currently, sur-
gical treatment of MRONJ has gained acceptance, as it was reported
to have a success rate of over 85%, while conservative treatment
success rate was limited to 15% (Nicolatou-Galitis et al., 2011;
Ristow et al., 2015). The initial reports of DRONJ discouraged the
Fig. 1. DRONJ developed spontaneously in a 71-year-old woman (case 42): a) two maxillary lesions, stage 1 on the right side and stage 3 on the left, b) and d) elevation of
mucoperiosteal flap reveals a small osteonecrotic lesion on the right side and a large area of necrotic bone on the left side, c and e) the intraoperative fluorescence view prior to
removal of the necrotic bone, f) the resulting oro-antral communication after removal of the necrotic bone on the left side, g) and h) After complete removal of the necrotic bone
parts and smoothening of sharp bony edges, the fluorescence was homogenously green, i) the size of the necrotic bone on the right side is less than the half of that on the left side, j)
preoperative panoramic radiograph showed an alveolar defect and sequestration on the left side and diffuse sclerosis on the right side, k) and l) representative axial and coronal CT
scans without contrast showed obliteration of the left maxillary sinus indicating maxillary sinus involvement, while the right maxillary sinus was normal, and the sequestration on
the left maxillary alveolar process.
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surgical treatment and reported spontaneous healing of DRONJ
(Taylor et al., 2010; Diz et al., 2012). Nevertheless, recent reports
have shown that surgical treatment of DRONJ has achieved good
treatment outcomes (Otto et al., 2013; You et al., 2015; Favia et al.,
2016; Hoefert et al., 2017). Hoefert et al. reported a complete
healing in 80% of patients treated with major surgery and only 20%
patients treated non-operatively (Hoefert et al., 2017). In the pre-
sent study, surgical treatment has achieved complete healing in
71.7% of the treated lesions. The success rate of fluorescence-guided
osteotomy (77.3%) was higher than that of the conventional surgery
(67.7%). A prospective study of 54 MRONJ patients treated with
fluorescence-guided surgery reported complete mucosal healing in
86.2% of the lesions (Otto et al., 2016). Indeed, this technique is a
reliable treatment option that aids not only in complete removal of
necrotic tissue but also in reserving the vital bone underneath.
In this study, about half of the patients had a previous intake of
bisphosphonates (49.2 %), while denosumab was the only
administered antiresorptive drug in 50.8% of the cohort.
Bisphosphonates can affect bone turnover even after years of their
discontinuation (Boonen et al., 2012). Bone turnover markers
(BTMs) increase slowly after cessation of bisphosphonates with a
slow increase to their level before treatment within 3e60 months
(Boonen et al., 2012). Based on that, prior intake of bisphospho-
nates might increase the risk of MRONJ. In addition, one can as-
sume that it might increase the severity of the osteonecrosis or
complicate the treatment. These findings, however, have not been
seen in a comparison between a bisphosphonate-naïve patient
group and that with a history of bisphosphonates. Indeed, there is
no statistically significant difference between the two groups in
regards to clinical characteristics, MRONJ stage, number of deno-
sumab doses, preceding oral events and treatment outcomes. A
slightly lower number of denosumab injections were recorded for
patients with bisphosphonate use; however this difference re-
mains statistically insignificant. The present study was the first to
Fig. 2. a) The clinical presentation of DRONJ lesion in a 72-year-old female patient (case 33) who had been treated with denosumab for osteoporosis, b) panoramic radiograph
showing 6 unit bridge with periodontitis in relation to abutment teeth, c) intraoperative view after mucoperiosteal flap elevation and extraction of the lateral incisors, d) fluo-
rescence image prior to necrotic bone removal reveals diminished fluorescence at the area of necrosis, e) fluorescence image after removal of the necrotic bone, f) healing was
evident 6 months postoperatively, g) panoramic radiograph shows healing of the site 6 months postoperatively.
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establish this comparison, perhaps due to the limited number of
patients in the previous case series. Nevertheless, prospective
studies with large sample size are necessary to confirm these
results.
The present retrospective study has some limitations. First,
the retrospective nature of this study did not allow us to draw
final conclusions regarding the treatment modalities and the
effect of denosumab discontinuation. Second, our results are
based on analysis of a small sample size due to the rarity of
DRONJ. Third, information on some clinical variables was
missing. However, important preliminary considerations can be
withdrawn from the present study as it included the largest
cohort studied to date. Retrospective studies in medicine,
especially for rare diseases, are of great importance to under-
stand disease course and pathophysiology and to identify its
optimal management. Well-controlled prospective studies are
required to further investigate our preliminary findings,
particularly in relation to systemic and local risk factors,
denosumab holiday, treatment modalities and treatment out-
comes, as well as the effect of previous bisphosphonate intake
on DRONJ severity and treatment outcomes.
5. Conclusion
In conclusion, osteonecrosis of the jaw in patients treated with
denosumab seems to be a relevant concern in antiresorptive drug
therapy. The applications of this innovative medication are ex-
pected to expand, and subsequently the prevalence of DRONJ is
expected to increase. Within the limitations of this retrospective
study, characteristics of DRONJ were investigated. DRONJ tends to
develop after administration of 16.4 doses. The previous use of
bisphosphonates does not appear to affect DRONJ severity or
treatment response. Based on our findings, we recommend sur-
gical treatment, particularly fluorescence-guided surgery, to allow
complete removal of necrotic bone and to prevent ONJ
progression.
Table 6
Demographic and clinical characteristics of BP-naïve versus noneBP-naïve patients.
Variable BP-naïve patients NoneBP-naïve patients P-value
Number of patients, n (%) 32 (50.8%) 31 (49.2%)
Age (mean in years) 69.5 ± 10 70.6 ± 8.4
Gender, n (%) NS
Female 18 (56.3%) 19 (61.3%)
Male 14 (43.8%) 12 (38.7%)
Indications for denosumab use, n (%) NS
Breast cancer 14 (43.8%) 13 (42%)
Prostate cancer 8 (25%) 9 (29%)
Osteoporosis 4 (12.5%) 5 (16%)
Kidney cancer 3 (9.4%) 1 (3.2%)
Multiple myeloma 1 (3.1%) 1 (3.2%)
Thyroid cancer 1 (3.1%) 1 (3.2%)
Lung cancer 0 1 (3.2%)
Melanoma 1 (3.1%) 0
Comorbidities, n (%) NS
Chemotherapy 18 (72%) 23 (79.3%)
Diabetes mellitus 5 (7.9%) 4 (6.3%)
Corticosteroids 1 (1.6%) 6 (9.5%)
Rheumatoid arthritis 2 (3.2%) 4 (6.3%)
Local factors, n (%) NS
Extraction 14 (4.8%) 14 (45.2%)
Periodontitis 1 (3.1%) 5 (16.1%)
Local trauma from ill-fitted denture 1 (3.1%) 3 (9.7%)
Extraction and local trauma 2 (6.3%) 1 (3.2%)
Extraction and periodontitis 2 (6.3%) 1 (3.2%)
Implant placement 1 (3.1%) 1 (3.2%)
Peri-implantitis 1 (3.1%) 0
Ridge augmentation 1 (3.1%) 0
Unknown 8 (25%) 5 (16.1%)
Extraction, periodontitis, peri-implantititis 1 (3.1%) 0
Scaling and root planing due to periodontitis 0 1 (3.2%)
Number of doses 17.5 ± 10.6 15.3 ± 14.6 NS
Time between last dose and MRONJ onset (mean in days) 20.8 ± 7.7 28 ± 25 NS
Stage, n (%) NS
Stage 0 2 (5.7%) 2 (5.9%)
Stage 1 2 (5.7%) 4 (11.8%)
Stage 2 25 (71.4%) 24 (70.6%)
Stage 3 6 (17.1%) 4 (11.8%)
Site, n (%) NS
Mandible 25 (71%) 18 (58%)
Maxilla 8 (23%) 9 (29%)
Both 2 (6%) 4 (13%)
Treatment, n (%) NS
Surgical 31 (97%) 29 (93.5%)
Non-surgical 1 (3%) 2 (6.5%)
Treatment outcome, n (%) NS
Healing 19 (68%) 19 (79.2%)
Non-healing 5 (18%) 3 (12.5%)
Partial healing 4 (14%) 2 (8.3%)
BPs: bisphosphonates, NS: not significant.
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